<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="monograph-family" /><meta name="keywords" content="Immunosuppressants: rheumatic disease; Methotrexate: rheumatic disease; Azathioprine: rheumatic disease; Leflunomide; Ciclosporin: rheumatic disease; Cyclophosphamide: rheumatic disease; Lupus erythematosus: systemic; Polymyositis; Psoriatic arthritis" /><meta name="IX" content="Immunosuppressants: rheumatic disease; Methotrexate: rheumatic disease; Azathioprine: rheumatic disease; Leflunomide; Ciclosporin: rheumatic disease; Cyclophosphamide: rheumatic disease; Lupus erythematosus: systemic; Polymyositis; Psoriatic arthritis" /><title>Drugs affecting the immune response: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="5304.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="5304.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=5304.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2077.htm">10 Musculoskeletal and joint diseases</a> &gt; <a href="5182.htm">10.1 Drugs used in rheumatic diseases and gout</a> &gt; <a href="5288.htm">10.1.3 Drugs that suppress the rheumatic disease process</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="5302.htm" title="Previous: HYDROXYCHLOROQUINE SULPHATE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="17371.htm" title="Next: AZATHIOPRINE">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_5304">Drugs affecting the immune response</h1><?highlighter on?><div id="pC" class="jN"><div><p><b><span>Methotrexate</span></b> is a disease-modifying antirheumatic drug suitable for
moderate to severe rheumatoid arthritis. <b><span>Azathioprine</span></b>, <b><span>ciclosporin</span></b>, <b><span>cyclophosphamide</span></b>, <b><span>leflunomide</span></b>, and the <b>cytokine modulators</b> are considered
more toxic and they are used in cases that have not responded to other
disease-modifying drugs.</p><p><b><span>Methotrexate</span></b> is usually given
in an initial dose of 7.5 mg by mouth once a week, adjusted according
to response to a maximum of 15 mg once a week (occasionally 20 mg
once a week). Regular full blood counts (including differential
white cell count and platelet count), renal and liver function tests
are required. In patients who experience mucosal or gastro-intestinal
side-effects with <span>methotrexate</span>, <span>folic
acid</span> 5 mg every week [unlicensed indication], on a different
day from the methotrexate, may help to reduce the frequency of such
side-effects.</p><p><b><span>Azathioprine</span> </b>is usually given
in a dose of up to 2.5 mg/kg daily in divided doses. Blood counts are needed to detect possible neutropenia or thrombocytopenia (usually resolved by reducing the dose). Nausea,
vomiting, and diarrhoea may occur, usually starting early during the
course of treatment, and may necessitate withdrawal of the drug; herpes
zoster infection may also occur.</p><p><b><span>Leflunomide</span> </b>acts on the immune system as a disease-modifying
antirheumatic drug. Its therapeutic effect starts after 4–6 weeks
and improvement may continue for a further 4–6 months. <span>Leflunomide</span>, which is similar in efficacy to <span>sulfasalazine</span> and <span>methotrexate</span>, may be chosen when these drugs
cannot be used. The active metabolite of <span>leflunomide</span> persists for a long period; active procedures to wash
the drug out are required in case of serious adverse effects, or before starting
treatment with another disease-modifying antirheumatic drug, or, in
men or women, before conception. Side-effects of <span>leflunomide</span> include bone-marrow toxicity; its immunosuppressive
effects increase the risk of infection and malignancy. </p><p><b><span>Ciclosporin</span></b> is licensed for severe
active rheumatoid arthritis when conventional second-line therapy
is inappropriate or ineffective. There is some evidence that <span>ciclosporin</span> may retard the rate of erosive progression
and improve symptom control in those who respond only partially to <span>methotrexate</span>.</p><div id="_5304.1"><p><b><span>Cyclophosphamide</span></b> (<a title=" Alkylating drugs" href="4677.htm#_4677">section 8.1.1</a>) may be used at a dose of 1 to 1.5 mg/kg daily
by mouth for rheumatoid arthritis with severe systemic manifestations
[unlicensed indication]; it is toxic and regular blood
counts (including platelet counts) should be carried out. <span>Cyclophosphamide</span> can also be given intravenously
in a dose of 0.5 to 1 g (with prophylactic <span>mesna</span>) for <i>severe systemic rheumatoid arthritis</i> and for
other connective tissue diseases (especially with active vasculitis),
repeated initially at fortnightly then at monthly intervals (according
to clinical response and haematological monitoring).</p></div><p>Drugs that affect the immune response are also
used in the management of severe cases of <i>systemic lupus erythematosus </i>and other connective tissue disorders. They are often given in conjunction
with <span>corticosteroids</span> for patients with severe or
progressive renal disease. They may be used in cases of <i>polymyositis </i>that are resistant to <span>corticosteroids</span>. They are
used for their corticosteroid-sparing effect in patients whose corticosteroid
requirements are excessive. <b><span>Azathioprine</span> </b>is usually used.</p><p>In the specialist
management of psoriatic arthritis affecting peripheral joints, leflunomide,
methotrexate, or azathioprine [unlicensed indication] may be used.</p></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_17371"><a href="17371.htm" title="AZATHIOPRINE">AZATHIOPRINE</a></li><li id="_17350"><a href="17350.htm" title="CICLOSPORIN">CICLOSPORIN</a></li><li id="_82653"><a href="82653.htm" title="LEFLUNOMIDE">LEFLUNOMIDE</a></li><li id="_5305"><a href="5305.htm" title="METHOTREXATE">METHOTREXATE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="5302.htm">Previous: HYDROXYCHLOROQUINE SULPHATE</a> | <a class="top" href="5304.htm#">Top</a> | <a accesskey="]" href="17371.htm">Next: AZATHIOPRINE</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>